Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K243684

    Validate with FDA (Live)

    Manufacturer
    Date Cleared
    2025-05-07

    (159 days)

    Product Code
    Regulation Number
    892.2050
    Age Range
    All
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticPediatricDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The BrightHeart View Classifier device is intended to analyze fetal 2D ultrasound images and video clips using machine learning techniques to automatically detect standard views during fetal heart scanning.

    The BrightHeart View Classifier device is intended to be used as an adjunct to the acquisition and interpretation of fetal anatomic ultrasound examinations at the second or third trimester of pregnancy performed with transabdominal probes.

    Device Description

    BrightHeart View Classifier is a cloud-based software-only device which uses artificial intelligence (AI) to detect standard views during fetal heart scanning in fetal ultrasound images and video clips.

    BrightHeart View Classifier is intended to be used by qualified, trained healthcare professional personnel in a professional prenatal ultrasound (US) imaging environment (this includes sonographers, MFMs, OB/GYN, and Fetal surgeons), to help fetal ultrasound examination acquisition and interpretation of 2D grayscale ultrasound by providing automatic classification of video clips and images into standard views, by automatically extracting example frames of standard views from video clips, and by automatically assessing whether the documentation of each standard view in video clips and images satisfies an acquisition protocol defined by the center. Annotated DICOM files generated by the device cannot be modified by the user.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the BrightHeart View Classifier, based on the provided FDA 510(k) Clearance Letter:

    1. Table of Acceptance Criteria and Reported Device Performance

    The FDA letter does not explicitly state pre-defined acceptance criteria values that the device needed to meet. Instead, it reports the device's performance metrics directly from the validation study. However, based on the performance report, we can infer the achieved performance and understand that these values were deemed sufficient for clearance.

    Performance MetricAcceptance Criteria (Implied)Reported Device Performance
    Mean Standard View Recognition SensitivityHigh (e.g., >0.90)0.939 (95% CI, 0.917 ; 0.960)
    Mean Standard View Recognition SpecificityHigh (e.g., >0.95)0.984 (95% CI, 0.973 ; 0.996)

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size: 2290 clinically acquired images and frames from video clips.
    • Number of Fetal Ultrasound Examinations: 579
    • Country of Origin of Data: U.S.A. and France.
    • Retrospective or Prospective: The document implies retrospective data ("clinically acquired images and frames").

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

    • Number of Experts: Two experts: "a sonographer and an MFM specialist".
    • Qualifications: "with experience in fetal echocardiography". Specific years of experience are not mentioned.

    4. Adjudication Method for the Test Set

    • Adjudication Method: Independence was maintained in the ground truth establishment. "The reference standard was derived from the dataset through a truthing process in which a sonographer and an MFM specialist with experience in fetal echocardiography determined the presence or absence of standard views on fetal ultrasound images. The truthing process was conducted independently of the BrightHeart View Classifier device." This indicates a consensus or independent review process, but not a specific 2+1 or 3+1 adjudication as those usually imply a tie-breaker. It seems like both experts independently determined the ground truth.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    • No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not explicitly described. The study evaluated the standalone performance of the AI device.

    6. Standalone (Algorithm Only Without Human-in-the-Loop) Performance

    • Yes, a standalone performance study was conducted. The reported sensitivity and specificity values are for the BrightHeart View Classifier identifying standard views on its own.

    7. Type of Ground Truth Used

    • Type of Ground Truth: Expert consensus (from a sonographer and an MFM specialist with experience in fetal echocardiography).

    8. Sample Size for the Training Set

    • The sample size for the training set is not explicitly stated in the provided document. The document only mentions that "The ultrasound examinations used for training and validation are entirely distinct from the examinations used in performance testing."

    9. How the Ground Truth for the Training Set Was Established

    • The document does not explicitly state how the ground truth for the training set was established. However, given the nature of the device and the ground truth method for the test set, it is highly probable that a similar expert review and annotation process was used for the training data.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1